



Luxembourg, 17 December 2025

Environmental and Social Completion Sheet (ESCS)¹

Overview

Project Name:	ONCOPEPTIDES (EGFF)
Project Number:	2020-0235
Country:	Sweden
Project Description:	Quasi equity financing to Oncopeptides - publicly listed Swedish biotech developing targeted therapies for difficult-to-treat hematological diseases such as relapsed and refractory multiple myeloma.

Summary of Environmental and Social Assessment at Completion

EIB notes the following Environmental and Social performance and key outcomes at Project Completion.

The Project was implemented in line with applicable legislation. Activities financed under the operation were limited to research, development, and clinical trials within existing authorised facilities, and the Promotor maintained robust internal quality and environmental management systems audited regularly. No significant environmental risks were identified during implementation, and the Project's nature ensured negligible environmental impact.

Mitigation measures were primarily procedural, focusing on compliance with Good Clinical Practice (GCP) and animal welfare standards under Directive 2010/63/EU. No construction, land acquisition, or biodiversity offsets were necessary. Adaptive management measures were applied during temporary clinical holds in 2021 to ensure patient safety and regulatory compliance, demonstrating effective risk management. Residual impacts were minimal and acceptable given the controlled research environment. Climate-related risks were not material, and no significant changes in GHG emissions were reported, as activities were confined to laboratory and clinical settings.

The Project delivered substantial social benefits by advancing treatment options for patients with relapsed and refractory multiple myeloma (RRMM) and related conditions.

Employment impacts were positive, with approximately 75 full-time equivalents dedicated to the Project, contributing to highly skilled job creation in the biotech sector. The Promoter also implemented rigorous pharmacovigilance and patient safety protocols during clinical trials, reinforcing social responsibility. Overall, the Project strengthened healthcare outcomes and supported innovation in oncology without adverse social consequences.

Summary opinion of Environmental and Social aspects at completion:

The Project demonstrated strong environmental and social performance. No significant environmental risks or residual impacts were identified. Social outcomes included job creation, knowledge transfer, and enhanced innovation capacity.

¹ The template is for ILs and FLs